Verana Health, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with Guardant Health Inc. that will allow biopharmaceutical researchers to access the combined resources of Verana's regulatory-grade, therapeutic-specific EHR curated datasets from medical societies and academic and community medical centers and Guardant's clinicogenomic testing data to accelerate the development of new therapies and enhance on-going patient care. Using the extensive datasets the collaboration provides, research scientists can more easily understand and further validate correlations between molecular biomarkers, treatment decisions and clinical outcomes. For example, from an urology perspective novel use cases of combining genomics data with NMIBC EHR curated data could enhance understanding the patient journey in risk refinement beyond stage/grade, lead to better treatment selection insights (i.e., who benefits from Bacillus Calmette-Guerin (BCG), the standard of care for most Non-muscle invasive bladder cancer (NMIBC) patients vs.
who needs earlier escalation, and validate biomarker measures (e.g., Tumor Mutational Burden (TMB)) using real-world response and outcome endpoints. Ultimately, the combination provides greater insights into existing research data with comprehensive real-world data?including critical longitudinal serial testing information?needed to optimize drug development and accelerate programs that treat cancer across diverse patient populations. Guardant's extensive real-world longitudinal serial testing datasets span all stages of the disease, from initial tumor profiling for therapy selection to recurrence and therapy response monitoring, while Verana Health's highly curated data tracks a patient's complete cancer care journey, drawing from both academic and community care center settings.
This new collaboration with Guardant deepens Verana Health's data by expanding its breadth into solid tumors, particularly lung, breast, and colorectal cancers, creating a broader, more diverse data set with considerable patient overlap for enhanced clinical insights.
